Factors associated with drug–induced visual hallucinations in Parkinson's disease
- First Online:
Visual hallucinations are common in medicationtreated Parkinson's disease (PD) patients. Although their etiology is unknown several factors seem to be involved in their pathogenesis. The aim of this study was to identify possible risk factors and determine clinical characteristics associated with the development of visual hallucinations in PD.
166 consecutive patients fulfilling clinical criteria for PD were studied. During a semi–structured interview, demographic characteristics and clinical variables were recorded. Motor, cognitive and psychiatric status was also assessed. Patients with and without visual hallucinations were compared using non–parametric tests, and logistic regression was applied to significant data.
During the month before evaluation 20.4% of our patients experienced visual hallucinations (11.4% benign, 9% malignant). Logistic regression analysis identified three factors independently associated with visual hallucinations: long duration of Parkinson's disease, dementia, and disease severity as measured by the UPDRS total score.
Our findings indicate that apart from well established risk factors such as cognitive impairment and disease duration, disease severity is also important for the development of visual hallucinations in PD. Furthermore, the presence of bradykinesia and instability, the absence of tremor and the severity of rigidity and bradykinesia (limb and axial) may act as cofactors.
Key wordsParkinson's disease hallucinations risk factors clinical phenotype
Unable to display preview. Download preview PDF.
- 3.American Psychiatric Association (1987) Diagnostic and Statistical Manual for Psychiatric Disorders. Revised third edition (ed) American Psychiatric Association. Washington, DCGoogle Scholar
- 4.Barclay CL, Hildebrand K, Gray P, et al. (1997) Risk factors for the development of psychosis in Parkinson's disease. Mov Disord 12(Suppl. 1):108Google Scholar
- 7.7. Fahn S, Elton RL, Committee (1987) MotUd, Unified Parkinson's disease rating scale in Recent developments in Parkinson's disease. Macmillan healthcare information, pp 153–163Google Scholar
- 27.Oertel WH (2000) Pergolide versus L–dopa (PELMOPET). Mov Disord. 15(Suppl. 3):4Google Scholar
- 34.Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson's disease, in:Gillingham FD (ed) Third symposium of Parkinson's disease, IMl, Livingstone:Edinburgh, pp 152–157Google Scholar
- 36.Tanner CM, Vogel C, Goetz CG (1983) Hallucinations in Parkinson's disease:a population study. Ann Neurol 14:136Google Scholar